EUVIMEDEUVIMED entdecken
Crossref

Engineering glypican-3–directed CAR-NK cell therapies for hepatocellular carcinoma

Haroonrashid M. Hattiwale, Atahar Husein, Shaista Parveen, Mohammad Azhar Kamal, Mohiuddin Khan Warsi, Asma Naseem, Syed Arif Hussain, Azfar Jamal

Journal of King Saud University – Science · 14.11.2026 · 1-14

DOI: 10.25259/jksus_600_2026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of King Saud University – Science, online erschienen am 14.11.2026. Verfasst von Haroonrashid M. Hattiwale und 7 weiteren Autor:innen. Die Arbeit nennt 105 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment of hepatocellular carcinoma (HCC) using adoptive cell therapy is still challenging because of the heterogeneity of antigens expressed on tumor cells and highly suppressive liver microenvironment. Glypican-3 (GPC3) has been identified as one of the most promising therapeutic targets as it is highly expressed in HCC cells but has low expression in normal adult liver tissue. Over the past few years, natural killer (NK) cells have emerged as a promising platform for chimeric antigen receptor (CAR) engineering. Compared with CAR-T cells, CAR-NK cells can be used in allogeneic settings and are generally associated with lower inflammatory toxicity. Advanced CAR technologies, including improved antigen-binding domains and NK-specific signaling domains such as DAP10, DAP12, and 2B4, have enhanced NK-cell activation and cytotoxic activity. Cytokine support systems like IL-15 and IL-21, along with synthetic biology approaches such as hypoxia-responsive systems and logic-gated receptors, are being explored to improve the performance of CAR-NK cells. However, challenges such as immunosuppressive signaling, metabolic stress, and limited immune-cell infiltration in the hepatic tumor microenvironment still need to be addressed. This review discusses recent advances in the development of GPC3-targeted CAR-NK therapies and highlights strategies that may improve their therapeutic potential in HCC.

Zitieren

APA

Hattiwale, H. M., Husein, A., Parveen, S., Kamal, M. A., Warsi, M. K., Naseem, A., Hussain, S. A., & Jamal, A. (2026). Engineering glypican-3–directed CAR-NK cell therapies for hepatocellular carcinoma. Journal of King Saud University – Science, 0, 1-14. https://doi.org/10.25259/jksus_600_2026

Vancouver

Hattiwale HM, Husein A, Parveen S, Kamal MA, Warsi MK, Naseem A, et al. Engineering glypican-3–directed CAR-NK cell therapies for hepatocellular carcinoma. Journal of King Saud University – Science. 2026;0:1-14. doi:10.25259/jksus_600_2026

BibTeX
@article{Hattiwale2026,
  author = {Hattiwale, Haroonrashid M. and Husein, Atahar and Parveen, Shaista and Kamal, Mohammad Azhar and Warsi, Mohiuddin Khan and Naseem, Asma and Hussain, Syed Arif and Jamal, Azfar},
  title = {Engineering glypican-3–directed CAR-NK cell therapies for hepatocellular carcinoma},
  journal = {Journal of King Saud University – Science},
  year = {2026},
  volume = {0},
  pages = {1--14},
  doi = {10.25259/jksus_600_2026}
}
Kostenlos starten →